文献速递临床免疫分子诊断

抗Endophilin A2自身抗体可作为乳腺癌早期诊断的新型生物标志物

Autoantibodies against Endophilin A2 as a novel biomarker are beneficial to early diagnosis of breast cancer.
PubMed 文献 · Clin Chim Acta · 2024-05-23

该研究采用间接ELISA检测不同来源和分期癌症患者血清中抗Endophilin A2(EA2)抗体水平,并用ROC曲线和分布曲线评估诊断准确性及参考范围。结果显示乳腺癌患者抗EA2抗体水平显著高于健康对照(P<0.0001),早期乳腺癌AUC为0.8014,远处转移者AUC为0.7885。结论认为抗EA2抗体是乳腺癌早期诊断的新型血液生物标志物,尚需更大规模队列研究验证。

要点

  • 乳腺癌患者血清抗EA2抗体水平显著高于健康对照(P<0.0001)。
  • 早期乳腺癌诊断AUC为0.8014,远处转移者AUC为0.7885。
  • 抗EA2抗体滴度与乳腺癌患者血清EA2抗原水平相关。

核心结论

  • 抗EA2抗体是乳腺癌早期诊断的新型血液生物标志物,值得在更大规模队列研究中进一步验证。

研究设计与样本

  • 采用间接ELISA分析不同来源和分期癌症患者血清中抗EA2抗体水平。
  • 用ROC曲线下面积和分布曲线确定诊断准确性和参考范围。
  • 用夹心ELISA测定血清中EA2抗原水平。

主要发现

  • 乳腺癌患者血清抗EA2抗体水平高于健康对照(P<0.0001)。
  • 肝癌(P=0.0005)、胃癌(P=0.0026)和结肠癌(P=0.0349)患者抗EA2抗体水平也高于健康对照。
  • 直肠癌(P=0.1151)、白血病(P=0.7508)和肺癌(P=0.2247)患者抗EA2抗体水平与健康对照无显著差异。
  • 乳腺癌诊断价值最高,早期病例AUC=0.8014,远处转移病例AUC=0.7885。
  • 乳腺癌患者血清抗EA2抗体滴度与EA2抗原水平相关。

局限性

  • 结论指出需在更大规模队列研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to the lack of early symptoms, breast cancer is frequently overlooked, leading to distant metastases and multi-organ lesions that directly threaten patients' lives. We have identified a novel tumor marker, antibodies to endophilin A2 (EA2), to improve early diagnosis of breast cancer. METHODS: Antibody levels of EA2 were analyzed in sera of patients with cancers of different origins and stages by indirect enzyme-linked immunosorbent assay (ELISA). Diagnostic accuracy and reference range were determined by the area under the receiver operating curve and distribution curve. The levels of EA2 antigen in sera were determined by sandwich ELISA. RESULTS: The levels of antibodies against EA2 were higher in sera of patients with breast cancer (P < 0.0001), liver cancer (P = 0.0005), gastric cancer (P = 0.0026), and colon cancer (P = 0.0349) than those in healthy controls, but not in patients with rectal cancer (P = 0.1151), leukemia (P = 0.7508), or lung cancer (P = 0.2247). The highest diagnostic value was for breast cancer, particularly in early cases (AUC = 0.8014) and those with distant metastases (AUC = 0.7885). The titers of EA2 antibodies in sera were correlated with levels of EA2 antigen in breast cancer patients. CONCLUSION: Antibodies to EA2 are novel blood biomarkers for early diagnosis of breast cancer that warrants further study in larger-scale cohort studies.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Li X, Li X, Zhang K, et al. Autoantibodies against Endophilin A2 as a novel biomarker are beneficial to early diagnosis of breast cancer. Clin Chim Acta. 2024. PMID: 38796051. doi:10.1016/j.cca.2024.119748

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。